FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Christophe Hézode

Research Profile

Disorders

Chemicals & Drugs

Living Beings

Hepacivirus

Procedures

Drug Therapy, Combination

Concepts & Ideas

Physiology

Anatomy

Livers

Co-author Network

Publications

TOP 3
Marc Bourlière; Hélène Fontaine; Christophe Hézode; Stanislas Pol; Astrid Wendt; Jean-Pierre Bronowicki
How to optimize HCV therapy in genotype 1 patients with cirrhosis.
Stanislas Pol; Robert W Reindollar; Vinod K Rustgi; Harvey A Tatum; Paul J Thuluvath; Megan Wind-Rotolo; Philip D Yin; Gary A Abrams; Norbert Bräu; Jean-Pierre Bronowicki; Ulysses Diva; Greg T Everson; Reem H Ghalib; Dennis Hernandez; Christophe Hézode; Robert Hindes; Eric A Hughes; Joseph K Lim; Claudia Martorell; Fiona McPhee; David W Morris; Steven Schnittman
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.
Patrice Cacoub; Nicolas Dupin; Geoffrey Dusheiko; Christophe Hézode; Jann Lübbe; Odile Picard; Ramon Pujol; Marc Bourlière; Peter Buggisch; Siegfried Segaert; Bing Thio; Jean-Claude Roujeau
Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Christophe Hézode (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Marc Bourlière; Hélène Fontaine; Christophe Hézode; Stanislas Pol; Astrid Wendt; Jean-Pierre Bronowicki
How to optimize HCV therapy in genotype 1 patients with cirrhosis.
Liver international : official journal of the International Association for the Study of the Liver 2013;33 Suppl 1():46-55.
2012: Stanislas Pol; Robert W Reindollar; Vinod K Rustgi; Harvey A Tatum; Paul J Thuluvath; Megan Wind-Rotolo; Philip D Yin; Gary A Abrams; Norbert Bräu; Jean-Pierre Bronowicki; Ulysses Diva; Greg T Everson; Reem H Ghalib; Dennis Hernandez; Christophe Hézode; Robert Hindes; Eric A Hughes; Joseph K Lim; Claudia Martorell; Fiona McPhee; David W Morris; Steven Schnittman
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.
The Lancet infectious diseases 2012;12(9):671-7.
2012: Patrice Cacoub; Nicolas Dupin; Geoffrey Dusheiko; Christophe Hézode; Jann Lübbe; Odile Picard; Ramon Pujol; Marc Bourlière; Peter Buggisch; Siegfried Segaert; Bing Thio; Jean-Claude Roujeau
Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals.
Journal of hepatology 2012;56(2):455-63.
2012: Christoph Sarrazin; Stefan Zeuzem; Christophe Hézode; Jean-Michel Pawlotsky
Antiviral strategies in hepatitis C virus infection.
Journal of hepatology 2012;56 Suppl 1():S88-100.
2011: Christophe Hézode
Direct-acting antiviral (DAA) actions in treatment-naïve patients.
Clinics and research in hepatology and gastroenterology 2011;35 Suppl 2():S52-8.
2011: Christophe Hézode
Oral combination therapy: future hepatitis C virus treatment?
Journal of hepatology 2011;55(4):933-5.
2011: Christophe Hézode; V Leroy; Ariane Mallat; Magali Bouvier-Alias; Laurent Castéra; I Rosa; Françoise Roudot-Thoraval; Dominique Roulot; J-M Pawlotsky
Liver stiffness diminishes with antiviral response in chronic hepatitis C.
Alimentary pharmacology & therapeutics 2011;34(6):656-63.
2011: Graham R Foster; Christophe Hézode; Gaston Picchio; Ben van Baelen; Rolf van Heeswijk; Lieselotte Verlinden; Ola Weiland; Jean-Pierre Bronowicki; Giampiero Carosi; Maria Beumont
Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections.
Gastroenterology 2011;141(3):881-889.e1.
2011: Stéphane Chevaliez; Bruno Costes; Patrice Couzigou; Juliette Foucher; Christophe Hézode; Vincent Leroy; Ariane Mallat; Philippe Mathurin; Laurent Alric; Gérard Babany; Magali Bouvier-Alias; Jean-Pierre Bronowicki; Mariem Charaf-Eddine; Isabelle Rosa; Stéphanie Rouanet; Alexandre Soulier; Albert Tran; Jean-Michel Pawlotsky
High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial).
Gastroenterology 2011;141(1):119-27.
2011: Charlotte E Costentin; Françoise Roudot-Thoraval; Elie Serge Zafrani; Fatiha Medkour; Jean-Michel Pawlotsky; Ariane Mallat; Christophe Hézode
Association of caffeine intake and histological features of chronic hepatitis C.
Journal of hepatology 2011;54(6):1123-9.
2011: Matthew L Albert; Armanda Casrouge; Stéphane Chevaliez; Christophe Hézode; Isabelle Rosa; Philippe Renard; Vincent Mallet; Arnaud Fontanet; Jean-Michel Pawlotsky; Stanislas Pol
Interferon induced protein 10 remains a useful biomarker of treatment failure in patients stratified for the interleukin-28B rs12979860 haplotype.
Hepatology (Baltimore, Md.) 2011;53(4):1410-1.
2010: Stéphane Chevaliez; Christophe Hézode
IL28B polymorphisms and chronic hepatitis C.
Gastroentérologie clinique et biologique 2010;34(11):587-9.
2010: Stéphane Chevaliez; Magali Bouvier-Alias; Syria Laperche; Christophe Hézode; Jean-Michel Pawlotsky
Performance of version 2.0 of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification.
Journal of clinical microbiology 2010;48(10):3641-7.
2010: Christophe Hézode; Jean-Michel Pawlotsky
[Chronic hepatitis B: antiviral treatment guidelines].
La Revue du praticien 2010;60(6):751-8.
2010: Laetitia Barbotte; Abdelhakim Ahmed-Belkacem; Stéphane Chevaliez; Alexandre Soulier; Christophe Hézode; Henri Wajcman; Doug J Bartels; Yi Zhou; Andrzej Ardzinski; Nagraj Mani; B Govinda Rao; Shelley George; Ann D Kwong; Jean-Michel Pawlotsky
Characterization of V36C, a novel amino acid substitution conferring hepatitis C virus (HCV) resistance to telaprevir, a potent peptidomimetic inhibitor of HCV protease.
Antimicrobial agents and chemotherapy 2010;54(6):2681-3.
2009: Florence Legrand-Abravanel; Philippe Colson; Hélène Leguillou-Guillemette; Laurent Alric; Isabelle Ravaux; Françoise Lunel-Fabiani; Magali Bouviers-Alias; Pascale Trimoulet; Marie Laure Chaix; Christophe Hézode; Juliette Foucher; Hélène Fontaine; Anne-Marie Roque-Afonso; Michèle Gassin; Evelyne Schvoerer; Catherine Gaudy; Bruno Roche; Michel Doffoël; Louis D'alteroche; Sophie Vallet; Yazid Baazia; Bruno POZZETTO; Vincent Thibault; Jean-Baptiste Nousbaum; Dominique Roulot; Henry Coppere; Thierry Poynard; Thierry Poinard; Christopher Payan; Jacques Izopet
Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy.
Journal of medical virology 2009;81(12):2029-35.
2009: Christophe Hézode; Nicole Forestier; Geoffrey Dusheiko; Peter Ferenci; Stanislas Pol; Tobias Goeser; Jean-Pierre Bronowicki; Marc Bourlière; SHAHIN GHARAKHANIAN; Leif Bengtsson; Lindsay McNair; Shelley George; Tara Kieffer; Ann Kwong; Robert S Kauffman; John Alam; Jean-Michel Pawlotsky; Stefan Zeuzem
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
The New England journal of medicine 2009;360(18):1839-50.
2009: Coralie Pallier; Christophe Rodriguez; Rozenn Brillet; patrice nordmann; Christophe Hézode; Jean-Michel Pawlotsky
Complex dynamics of hepatitis B virus resistance to adefovir.
Hepatology (Baltimore, Md.) 2009;49(1):50-9.
2008: Aurélie Piodi; Philippe Chouteau; Hervé Lerat; Christophe Hézode; Jean-Michel Pawlotsky
Morphological changes in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and relationship with steatosis.
Hepatology (Baltimore, Md.) 2008;48(1):16-27.
2008: Christophe Hézode; Elie Serge Zafrani; Françoise Roudot-Thoraval; Charlotte Costentin; Ali Hessami; Magali Bouvier-Alias; Fatiha Medkour; Jean-Michel Pawlostky; Sophie Lotersztajn; Ariane Mallat
Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C.
Gastroenterology 2008;134(2):432-9.
2007: Stéphane Chevaliez; Rozenn Brillet; Ester Lázaro; Christophe Hézode; Jean-Michel Pawlotsky
Analysis of ribavirin mutagenicity in human hepatitis C virus infection.
Journal of virology 2007;81(14):7732-41.
2007: Christophe Hézode; Stéphane Chevaliez; Magali Bouvier-Alias; Françoise Roudot-Thoraval; Rozenn Brillet; Elie Serge Zafrani; Daniel Dhumeaux; Jean-Michel Pawlotsky
Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily.
Journal of hepatology 2007;46(5):791-6.
2006: Jean-Pierre Bronowicki; Denis Ouzan; Tarik Asselah; Hervé Desmorat; Jean-Pierre Zarski; Juliette Foucher; Marc Bourlière; Christophe Renou; Albert Tran; Pascal Melin; Christophe Hézode; Michelle Chevalier; Magali Bouvier-Alias; Stéphane Chevaliez; François Montestruc; Isabelle Lonjon-Domanec; Jean-Michel Pawlotsky
Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
Gastroenterology 2006;131(4):1040-8.
2006: Corinne Bonny; H Fontaine; T Poynard; Christophe Hézode; D Larrey; P Marcellin; Marc Bourlière; Jean-Pierre Bronowicki; P Merle; J P Zarski; T Sapey; C Guillemard; Sylvie Ughetto; Cécile Henquell; C Nicolas; C Roche; K Randl; Gilles Bommelaer; Armand Abergel
Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study.
Alimentary pharmacology & therapeutics 2006;24(4):593-600.
2006: Coralie Pallier; Laurent Castéra; Alexandre Soulier; Christophe Hézode; patrice nordmann; Daniel Dhumeaux; Jean-Michel Pawlotsky
Dynamics of hepatitis B virus resistance to lamivudine.
Journal of virology 2006;80(2):643-53.
2005: Christophe Hézode; Françoise Roudot-Thoraval; Son Nguyen; Pascale Grenard; Boris Julien; Elie Serge Zafrani; Jean-Michel Pawlotsky; Jean-Michel Pawlostky; Daniel Dhumeaux; Sophie Lotersztajn; Ariane Mallat
Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C.
Hepatology (Baltimore, Md.) 2005;42(1):63-71.
2005: Karine Gourlain; Alexandre Soulier; Bertrand Pellegrin; Magali Bouvier-Alias; Christophe Hézode; Françoise Darthuy; Jocelyne Rémiré; Jean-Michel Pawlotsky
Dynamic range of hepatitis C virus RNA quantification with the Cobas Ampliprep-Cobas Amplicor HCV Monitor v2.0 assay.
Journal of clinical microbiology 2005;43(4):1669-73.
2004: Keyur Patel; Stuart Gordon; Ira Jacobson; Christophe Hézode; Esther Oh; Katie M Smith; Jean-Michel Pawlotsky; John G McHutchison
Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients.
Journal of hepatology 2004;41(6):935-42.
2004: Christophe Hézode; Françoise Roudot-Thoraval; Elie Serge Zafrani; Daniel Dhumeaux; Jean-Michel Pawlotsky
Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections.
Journal of viral hepatitis 2004;11(5):455-8.
2004: Laurent Castéra; Christophe Hézode; Françoise Roudot-Thoraval; Isabelle Lonjon; Elie Serge Zafrani; Jean-Michel Pawlotsky; Daniel Dhumeaux
Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis.
Gut 2004;53(3):420-4.
2003: Christophe Hézode; Isabelle Lonjon; Françoise Roudot-Thoraval; Jean-Michel Pawlotsky; Elie Serge Zafrani; Daniel Dhumeaux
Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C, and specific influence of steatosis: a prospective study.
Alimentary pharmacology & therapeutics 2003;17(8):1031-7.
2003: Laurent Castéra; Christophe Hézode; Françoise Roudot-Thoraval; Anne Bastie; Elie Serge Zafrani; Jean-Michel Pawlotsky; Daniel Dhumeaux
Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies.
Gut 2003;52(2):288-92.
2003: Christophe Hézode; Isabelle Lonjon; Françoise Roudot-Thoraval; J-P Mavier; Jean-Michel Pawlotsky; Elie Serge Zafrani; Daniel Dhumeaux
Impact of smoking on histological liver lesions in chronic hepatitis C.
Gut 2003;52(1):126-9.
2002: Christophe Duvoux; Georges-Philippe Pageaux; Claire Vanlemmens; Françoise Roudot-Thoraval; Anne-Laure Vincens-Rolland; Christophe Hézode; Philippe Gaulard; Jean-Philippe Miguet; Dominique Larrey; Daniel Dhumeaux; Daniel Cherqui
Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients.
Transplantation 2002;74(8):1103-9.
2002: Christophe Duvoux; David Zanditenas; Christophe Hézode; Anthony Chauvat; Jean-Luc Monin; Françoise Roudot-Thoraval; Ariane Mallat; Daniel Dhumeaux
Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study.
Hepatology (Baltimore, Md.) 2002;36(2):374-80.
2002: Daniel Dhumeaux; Christophe Hézode
[Chronic hepatitis C with repeatedly normal transaminase levels].
Romanian journal of gastroenterology 2002;11(2):129-33.
2002: Christophe Hézode
[Treatment of patients with chronic hepatitis C who never had been treated].
Gastroentérologie clinique et biologique 2002;26 Spec No 2():B38-49.
2002: Christophe Duvoux; Anh Tran Ngoc; Liliane Intrator; Christophe Hézode; Georgios Germanidis; Jean-Michel Pawlotsky; Daniel Cherqui; Daniel Dhumeaux
Hepatitis C virus (HCV)-related cryoglobulinemia after liver transplantation for HCV cirrhosis.
Transplant international : official journal of the European Society for Organ Transplantation 2002;15(1):3-9.
2001: L Fartoux-Heymann; Christophe Hézode; Elie Serge Zafrani; Daniel Dhumeaux; Ariane Mallat
Acute fatal hepatitis related to sertraline.
Journal of hepatology 2001;35(5):683-4.
2000: Christophe Duvoux; Benoit Malassagne; JM Métreau; Christophe Hézode; Daniel Cherqui
[Synopsis: liver transplantation in adults: indications, results and postoperative follow-up].
Gastroentérologie clinique et biologique 2000;24(5):557-66.
2000: Jean-Michel Pawlotsky; Anne Bastie; Christophe Hézode; Isabelle Lonjon; Françoise Darthuy; Jocelyne Rémiré; Daniel Dhumeaux
Routine detection and quantification of hepatitis B virus DNA in clinical laboratories: performance of three commercial assays.
Journal of virological methods 2000;85(1-2):11-21.
1999: Christophe Hézode; Cécile Cazeneuve; O Coué; Françoise Roudot-Thoraval; Isabelle Lonjon; Anne Bastie; Christophe Duvoux; Jean-Michel Pawlotsky; Elie Serge Zafrani; Serge Amselem; Daniel Dhumeaux
Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions.
Journal of hepatology 1999;31(6):979-84.
1999: Françoise Foulet; Christophe Duvoux; C de Bièvre; Christophe Hézode; Stéphane Bretagne
Cutaneous phaeohyphomycosis caused by Veronaea bothryosa in a liver transplant recipient successfully treated with itraconazole.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1999;29(3):689-90.
1999: Christophe Hézode; Christophe Duvoux; Georgios Germanidis; Françoise Roudot-Thoraval; A L Vincens; Philippe Gaulard; Daniel Cherqui; Jean-Michel Pawlotsky; Daniel Dhumeaux
Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation.
Hepatology (Baltimore, Md.) 1999;30(3):775-8.
1999: Christophe Hézode; Cécile Cazeneuve; O Coué; Françoise Roudot-Thoraval; Jean-Michel Pawlotsky; Elie Serge Zafrani; S Amslem; Daniel Dhumeaux
Hemochromatosis C282Y mutation and histological fibrosis in patients with C virus chronic hepatitis.
Hepatology (Baltimore, Md.) 1999;29(4):1338.